

Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection

NCT06135922

Status	RECRUITING
Phase	Phase 1
Sponsor	Chinese PLA General Hospital
Enrollment	9 participants

Key Eligibility Criteria

Inclusion (4)

- Age 1-60 years, gender unlimited.
- Diagnosed with EBV associated-hemophagocytic lymphohistiocytosis (HLH) or EBV infection.
- Fully understood and informed the study and signed the ICF.
- Karnofsky Score ≥ 70 (age ≥ 16 y) or Lansky Score ≥ 50 (age < 16 y).

Exclusion (11)

- Patients with uncontrolled active aGVHD one day before TCR-T cell infusion.
- Patients with severe kidney disease (Cr $> 3 \times$ normal value), liver damage (TBIL $> 2.5 \times$ upper limit of normal value, ALT and AST $> 3 \times$ upper limit of normal value) or heart failure (NYHA heart function grade IV or left ventricular ejection fraction $< 50\%$) one week before TCR-T cell infusion.
- Anticipated to take immunosuppressive hormones on the day of TCR-T cell infusion.
- Use of immunosuppressive drugs or G-CSF within 2 weeks before PBMC blood collection.
- Have tumours, active and uncontrolled malignant diseases.
- ... and 6 more (see full listing online)

Locations (1 total)

Chinese PLA General Hospital, Beijing, Beijing Municipality, China